CD8A and B-cell chronic lymphocytic leukemia: Treatment of PBMCs from patients with CLL with increasing doses of EC-7072 exerted negligible effects on T cell numbers (Figure 2A) and viability (Figures 2C,D), finding no differences between CD4+ and CD8+ T cell subpopulations (Supplementary Figure 3).